Effects of metalloprotease inhibitors on smooth muscle endothelindashconverting enzyme activity
作者:Joseph L. Balwierczak、Paivi J. Kukkola、Paula Savage、Arco Y. Jeng
DOI:10.1016/0006-2952(94)00508-j
日期:1995.1
The enzyme responsible for the conversion of exogenous big endotheIin-1 to endothelin-1 by porcine coronary arterial smooth muscle has been shown to be a metalloprotease. The potencies of eight metalloprotease inhibitors for this endothelin-converting enzyme were determined. CGS 25015, CGS 26129, and thiorphan inhibited the enzyme activity monophasically with IC50 values of 2.6, 2.4, and 190 mu M, respectively. In contrast, the data obtained using phosphoramidon as an inhibitor were best fit by a two-site model. The biphasic concentration-response curve had IC50 values of 4.6 mu M and 2.2 mM. Three analogs of phosphoramidon were also tested for enzyme inhibition. Removal of the rhamnose moiety of phosphoramidon reduced the potency (IC50 = 15 mu M), whereas substitution of the rhamnose by N-[2-(2-naphthyl)ethyl] improved the potency (IC50 = 2.0 mu M). These results identify a thiol and a phosphonyl series of compounds as smooth muscle endothelin-converting enzyme inhibitors. The structure-activity relationships revealed that an aromatic or aliphatic group in the P-2' position or an aromatic group in the P-1 position of the inhibitor significantly increased the potency.
Biosynthetic reconstitution of deoxysugar phosphoramidate metalloprotease inhibitors using an N–P-bond-forming kinase
In the biosynthesis of phosphoramidon-like metalloprotease inhibitors three enzymes cooperate in the condensation of two amino acids and the subsequent attachment of a 6-deoxyhexose via a phosporamidate bridge.